The Fibrinolytic Response To Stanozolol In Normal Subjects

M Greaves, F Preston
1981 Thrombosis and Haemostasis  
It has been recognized for a number of years that fibrinolytic activity in patients with various forms of vascular disease may be enhanced by stanozolol (17-β-hydroxy-17α-methyl adrostano {3.2,- c } pyrazole ). However, little is known of its effect in normal healthy individuals. Also it is not known how quickly the drug exerts its effects. Two groups of eight normal healthy adults were studied. Seven subjects were included in both groups. Group A received stanozolol 5mgs b.d. Group B received
more » ... mgs daily. Before receiving the drug, two base line studies were performed on blood samples from each individual. Thereafter, blood samples were taken at 2,7, 10, 17, 24, 31 and 38 days after commencement of treatment. The following investigations were performed - haemoglobin, white cell count, platelet count, euglobulin clot lysis time (ECLT), fibrinogen (Fg), plasminogen (Pg), α2 macroglobulin (α2M), fibrin degradation products, serum albumin, liver enzymes. In Group A statistically significant increases in plasminogen activator activity, measured by the ECLT, and Pg were observed 2 days (P<0.05) and 10 days (P<0.05) respectively after administration of stanozolol; these remained elevated throughout the study. Also, significant reductions of plasma Fg (P<0.01) and α2M (P<0.05) occurred within 7 days of commencement of the drug and these also persisted throughout the six week period of the trial. Similar statistically-significant changes were also observed in Group B subjects in ECLT, Pg, α2M, although the induced changes were less predictable than those observed in Group A. These results indicate that stanozolol exerts significant and persistent enhancement of fibrinolysis in normal individuals.
doi:10.1055/s-0038-1653174 fatcat:w6im6ijs5fgtzig5rrax6adovu